Compare Alcon AG (ALC) vs Enovix Corporation (ENVX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Enovix Corporation — how do they compare? Alcon AG trades at $66.86 (market cap $32.69B), while Enovix Corporation trades at $5.05 (market cap $1.09B). The key difference: Alcon AG is far larger — about 30× Enovix Corporation's market cap, and Alcon AG pays a 0.54% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.
| ALC | ENVX | |
|---|---|---|
Market Cap | $32.69B | $1.09B |
Sector | Health | Technology |
52-Week High | $92.22 | $15.93 |
52-Week Low | $62.02 | $4.84 |
Enterprise Value | $36.28B | $1.10B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
ENVX trades at $5.62, up 4.85% today, but technical indicators signal a bearish trend with support at $5 and resistance at $6. The company reported Q1 2026 revenue above guidance and an EPS beat, yet remains unprofitable with a net margin of -499.64%. Analyst consensus is bullish with a $12.75 price target, driven by growth in silicon-anode batteries for AI devices, smart eyewear, and defense markets.
The stock offers high-risk, high-reward potential given its speculative growth story versus persistent losses. Key catalysts include scaling commercial production and smartphone qualification, but execution risks and cash burn require careful monitoring. Investors should weigh analyst optimism against fundamental challenges in the competitive battery sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
